Cognition Therapeutics ot present data from zervimesine Phase 2 study

Cognition Therapeutics (CGTX) announced that James Galvin, MD, MPH will present results from the Phase 2 ‘SHIMMER’ study of zervimesine in dementia with Lewy bodies during an oral presentation at the Alzheimer’s Association International Conference. -Zervimesine-treated participants tested 86% better on behavioral outcomes, 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo. “The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease,” stated Dr. Galvin. “My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB.”